SWITZERLAND’S LEADING STARTUP COMPETITION
Want to turn your innovative startup idea into reality?
Learn how >>venture>> can you support you.
News & Events
>>venture>> Kickoff in Zurich – Nov. 29
Don’t miss our Kickoff event in Zurich. Learn about how the competition works and meet experts, investors and entrepreneurs!
11 Oct 2022
Early-stage innovation got a kickstart in Western Switz...
>>venture>> kickstarted their 2023 edition at the innovation hub of Western Switzerland, EPFL.
24 Nov 2022
>>venture>> Introduction to Intellectual Property
This online seminar is hosted by the Swiss Federal Institute of Intellectual Property and...
16 Nov 2022
Why should you join >>venture>>?
Ready to turn your innovative business or NPO idea into reality? Then you’re a perfect match for >>venture>>, an annual competition that supports early-stage startups.
Awarding over half a million Swiss francs, each year we open our competition and invite you to attend our workshops, make connections in the Swiss startup scene and access our coaching and mentor network.
-min.jpg)
Prizes
Make your startup dreams a reality with up to CHF 150,000 in cash and a business consulting package from McKinsey & Company.
Network
Connect with mentors and get expert feedback. Make valuable contacts that will shape your future and get your business off the ground.
Visibility
Make connections in the Swiss startup scene and get access to investors and top business executives in Switzerland as well as media exposure.
Shaping the companies of tomorrow
We are extremely proud of our alumni. They have accomplished great feats, and we’re confident they will continue to do so. Here are some of their stories.
GLYCART
Biotech startup Glycart was a >>venture>> competition winner in 2000. Founded as a spinoff of the ETH, the company is an innovator in glycoengineering, or adding sugar chains to antibodies to make them more effective in fighting cancer and other diseases. The life-saving potential of this technology was recognized early on, prompting pharma giant Roche to acquire the startup for $235 million in 2005. A leukemia drug based on Glycart’s research received breakthrough therapy designation from the US Food and Drug Administration in 2013.
< Headquarter in Schlieren
Ready to venture forward?
Our Sponsors
 |  |  |
|---|---|---|
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |